Arcutis Biotherapeutics, Inc. (ARQT)
Largest Insider Buys in Sector
ARQT Stock Price History Chart
ARQT Stock Performance
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; …
Insider Activity of Arcutis Biotherapeutics, Inc.
Over the last 12 months, insiders at Arcutis Biotherapeutics, Inc. have bought $199,994 and sold $2.66M worth of Arcutis Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Arcutis Biotherapeutics, Inc. have bought $34.25M and sold $3.77M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $1.6M.
The last purchase of 21,052 shares for transaction amount of $199,994 was made by Heron Patrick J (director) on 2024‑03‑04.
List of Insider Buy and Sell Transactions, Arcutis Biotherapeutics, Inc.
| 2024-11-04 | Sale | See Remarks | 13,871 0.0117% | $8.68 | $120,459 | +12.04% | ||
| 2024-11-04 | Sale | See Remarks | 15,441 0.0131% | $8.68 | $134,093 | +12.04% | ||
| 2024-11-04 | Sale | See Remarks | 5,015 0.0042% | $8.68 | $43,551 | +12.04% | ||
| 2024-11-01 | Sale | director | 10,000 0.0085% | $8.65 | $86,541 | +0.58% | ||
| 2024-10-02 | Sale | SVP Chief Commercial Officer | 3,725 0.0035% | $10.01 | $37,295 | -6.30% | ||
| 2024-10-01 | Sale | director | 10,000 0.0086% | $9.26 | $92,616 | +1.36% | ||
| 2024-09-24 | Sale | Chief Financial Officer | 11,626 0.0098% | $9.48 | $110,264 | -3.42% | ||
| 2024-09-03 | Sale | director | 10,000 0.0088% | $10.77 | $107,695 | -6.76% | ||
| 2024-08-19 | Sale | See Remarks | 1,728 0.0014% | $8.29 | $14,318 | +13.29% | ||
| 2024-08-02 | Sale | See Remarks | 14,487 0.0122% | $9.02 | $130,648 | +5.51% | ||
| 2024-08-02 | Sale | See Remarks | 13,206 0.0111% | $9.02 | $119,106 | +5.51% | ||
| 2024-08-02 | Sale | See Remarks | 5,220 0.0044% | $9.02 | $47,064 | +5.51% | ||
| 2024-08-01 | Sale | director | 10,000 0.009% | $9.87 | $98,696 | +2.74% | ||
| 2024-07-01 | Sale | director | 10,000 0.0087% | $9.31 | $93,141 | 0.00% | ||
| 2024-06-04 | Sale | director | 10,000 0.0088% | $8.01 | $80,092 | +21.98% | ||
| 2024-05-30 | Sale | See Remarks | 23,000 0.0201% | $8.75 | $201,319 | +10.52% | ||
| 2024-05-29 | Sale | See Remarks | 49,952 0.0438% | $8.72 | $435,387 | +11.31% | ||
| 2024-05-28 | Sale | See Remark | 1,775 0.0016% | $9.01 | $15,988 | +7.21% | ||
| 2024-05-17 | Sale | SVP Chief Commercial Officer | 7,640 0.0066% | $8.98 | $68,582 | +3.38% | ||
| 2024-05-02 | Sale | See Remarks | 13,783 0.0122% | $8.74 | $120,433 | +8.60% |
Insider Historical Profitability
| Heron Patrick J | director | 8785284 7.5158% | $9.73 | 3 | 0 | <0.0001% |
| Watanabe Todd Franklin | See Remarks | 832392 0.7121% | $9.73 | 1 | 43 | +6.79% |
| Frazier Life Sciences VIII, L.P. | 10 percent owner | 8764232 7.4978% | $9.73 | 2 | 0 | +5.03% |
| ORBIMED ADVISORS LLC | 4267564 3.6509% | $9.73 | 2 | 0 | +10.62% | |
| SILVERSTEIN JONATHAN | 4267564 3.6509% | $9.73 | 2 | 0 | +10.62% |
Institutional Investor Ownership
| JENNISON ASSOCIATES LLC | $120.67M | 10.52 | 12.18M | +34.31% | +$30.82M | 0.08 | |
| Frazier Life Sciences Management L P | $87.06M | 7.59 | 8.79M | +0.24% | +$208,625.32 | 3.93 | |
| State Street | $87.05M | 7.59 | 8.78M | +475.99% | +$71.94M | <0.01 | |
| Suvretta Capital Management, LLC | $78.06M | 6.81 | 7.88M | -7.03% | -$5.9M | 3.3 | |
| Helm Capital Management LLC | $74.42M | 6.49 | 7.51M | +13.03% | +$8.58M | 2.2 |